<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-156067</identifier>
<setSpec>0367-2743</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">No disponible</dc:title>
<dc:description xml:lang="en">Erythema Nodosum leprosum (ENL) or type 2 Leprae reaction is a known complication affecting lepromatous and borderline lepromatous leprosy patients. ENL has been regarded as an immune complex-mediated disease or type III hypersensitivity reaction. ENL was associated with high serum tumour necrosis factor-alpha (TNF alpha) levels. Capsule Thalidomide (TLD) and systemic oral prednisolone are the two current effective drugs for the management of ENL by inhibiting TNF. Because of major adverse effects by these drugs, it is hypothesized to use an antidiabetic drug with good safety profile for managing the inflammations in ENL. The benefits of using metformin over the currently available drugs are its safety profile, available in market for long decades, can be given safely in pregnant women, wide range of dose selection and no much follow up special investigations. In addition metformin can be used as monotheraphy or in combination with low dose of steroids or in diabetic ENL patients. This hypothesis will encourage the researcher in field of leprosy to try with a safe drug (AU)</dc:description>
<dc:creator>Ali MKS, Showkath</dc:creator>
<dc:creator>Thangaraju, Pugazhenthan</dc:creator>
<dc:creator>Selvam T, Tamil</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El eritema nodoso leproso (ENL) o leprorreacción tipo 2 es una complicación que afecta a los pacientes de lepra lepromatosa y borderline lepromatosa. El ENL está considerado un episodio mediado por inmunocomplejos o reacción de hipersensibilidad de tipo III. También se asocia a niveles elevados séricos de factor de necrosis tumoral alfa (TNF-&amp;#945;). Los dos principios activos administrados para su control son la talidomida y la prednisolona orales, ya que ambos inhiben el TNF. Por los efectos adversos de estos medicamentos, proponemos el uso de un medicamento antidiabético con un buen perfil de seguridad para controlar la inflamación en el ENL. Los beneficios de la metformina sobre la medicación actual son su perfil de seguridad, disponibilidad en el mercado durante décadas, seguridad en mujeres embarazadas, amplio rango de dosis y no requiere complicados seguimientos de control. Además, la metformina se puede administrar como monoterapia o en combinación con dosis bajas de esteroides o en pacientes ENL diabéticos. Se propone investigar su administración en las ENL (AU)</dc:description>
<dc:source>Fontilles, Rev. leprol;30(5): 479-490, mayo-ago. 2016. tab, graf</dc:source>
<dc:identifier>ibc-156067</dc:identifier>
<dc:title xml:lang="es">Metformina, un medicamento antidiabético como agente terapéutico en el tratamiento dele ritema nodoso leproso crónico de moderado a severo</dc:title>
<dc:subject>^d4980^s22016</dc:subject>
<dc:subject>^d7182^s22000</dc:subject>
<dc:subject>^d4980^s22012</dc:subject>
<dc:subject>^d4980^s22067</dc:subject>
<dc:subject>^d8096^s22011</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d8096^s22012</dc:subject>
<dc:subject>^d8096^s22067</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d29591^s22073</dc:subject>
<dc:subject>^d23708^s22016</dc:subject>
<dc:subject>^d8862^s22073</dc:subject>
<dc:subject>^d8862^s22078</dc:subject>
<dc:subject>^d22622^s22020</dc:subject>
<dc:subject>^d23708^s22012</dc:subject>
<dc:subject>^d23708^s22067</dc:subject>
<dc:subject>^d7182^s22073</dc:subject>
<dc:subject>^d14171^s22020</dc:subject>
<dc:subject>^d8862^s22000</dc:subject>
<dc:type>article</dc:type>
<dc:date>201608</dc:date>
</metadata>
</record>
</ibecs-document>
